Gene Therapy

New Gene Therapy data have been reported by P. Revill and co-authors

Published in Gene Therapy Weekly, September 13th, 2007

"Panobinostat (LBH-589) is a member of the hydroxamic acid group of histone deacetylase (HDAC) inhibitors that have been shown to impede multiple pathways implicated in cancer and reverse epigenetic events associated with cancer, thereby reducing survival and inducing apoptosis in cancer cells," scientists in Barcelona, Spain report.

"Panobinostat is being investigated in various hematological malignancies, including chronic myelogenous leukemia (CML) and multiple myeloma, and in solid tumors. Preclinical data indicate efficacy against drug-resistant cancer cells, both as a single agent and in combination with other therapies," wrote P. Revill and colleagues.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2007-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry